| Original language | English (US) |
|---|---|
| Pages (from-to) | e86-e90 |
| Journal | British Journal of Haematology |
| Volume | 189 |
| Issue number | 3 |
| DOIs | |
| State | Published - May 1 2020 |
Keywords
- Hodgkin lymphoma
- autologous stem cell transplantation
- bendamustine
- brentuximab vedotin
- first salvage therapy
ASJC Scopus subject areas
- Hematology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma. / LaCasce, Ann S.; Bociek, R. Gregory; Sawas, Ahmed; Caimi, Paolo; Agura, Edward; Matous, Jeffrey; Ansell, Stephen M.; Crosswell, Howland E.; Islas-Ohlmayer, Miguel; Behler, Caroline; Cheung, Eric; Forero-Torres, Andres; Vose, Julie; O’Connor, Owen A.; Josephson, Neil; Wang, Yinghui; Advani, Ranjana.
In: British Journal of Haematology, Vol. 189, No. 3, 01.05.2020, p. e86-e90.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma
AU - LaCasce, Ann S.
AU - Bociek, R. Gregory
AU - Sawas, Ahmed
AU - Caimi, Paolo
AU - Agura, Edward
AU - Matous, Jeffrey
AU - Ansell, Stephen M.
AU - Crosswell, Howland E.
AU - Islas-Ohlmayer, Miguel
AU - Behler, Caroline
AU - Cheung, Eric
AU - Forero-Torres, Andres
AU - Vose, Julie
AU - O’Connor, Owen A.
AU - Josephson, Neil
AU - Wang, Yinghui
AU - Advani, Ranjana
N1 - Funding Information: The institutions of Ann S. LaCasce, R. Gregory Bociek, Ahmed Sawas, Paolo Caimi, Edward Agura, Jeffrey Matous, Stephen M. Ansell, Howland E. Crosswell, Miguel Islas‐Ohlmayer, Caroline Behler, Eric Cheung, Andres Forero‐Torres, Julie Vose, Owen A. O’Connor, and Ranjana Advani received funding from Seattle Genetics, Inc. to conduct the trial. Howland E. Crosswell, Neil Josephson, and Yinghui Wang, have equity ownership in Seattle Genetics, Inc. Julie Vose and Ahmed Sawas have received honoraria from Seattle Genetics, Inc. Jeffrey Matous and Caroline Behler have participated in a speakers’ bureau for Seattle Genetics, Inc and Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceuticals Limited. Owen A. O’Connor has received research funding from Seattle Genetics, Inc. Howland E. Crosswell has acted as a consultant for and has received travel expenses from Seattle Genetics, Inc. Neil Josephson was employed by Seattle Genetics, Inc. at the time this research was conducted. Yinghui Wang is employed by Seattle Genetics, Inc. Funding Information: The authors thank the patients and clinical study teams who participated in this research. Medical writing and editorial support were provided by Laurie LaRusso, Chestnut Medical Communications, and Eric Bertelsen, Seattle Genetics, Inc., and paid for by Seattle Genetics. This work was supported by research funding from Seattle Genetics, Inc.
PY - 2020/5/1
Y1 - 2020/5/1
KW - Hodgkin lymphoma
KW - autologous stem cell transplantation
KW - bendamustine
KW - brentuximab vedotin
KW - first salvage therapy
UR - http://www.scopus.com/inward/record.url?scp=85079362224&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079362224&partnerID=8YFLogxK
U2 - 10.1111/bjh.16499
DO - 10.1111/bjh.16499
M3 - Letter
C2 - 32048731
AN - SCOPUS:85079362224
VL - 189
SP - e86-e90
JO - British Journal of Haematology
JF - British Journal of Haematology
SN - 0007-1048
IS - 3
ER -